{"id":"W3083951977","doi":"10.1016/j.ccell.2020.08.007","title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial","year":2020,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":393,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; National Cancer Institute; Genentech; National Institutes of Health; Bristol-Myers Squibb Canada; Ono Pharmaceutical; Parker Institute for Cancer Immunotherapy; Breast Cancer Now; Exelixis; Meso Scale Diagnostics; Sanofi; Merck; Bayer Corporation; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Anthropological Association; Roche; Astellas Pharma US; Amgen; University of Texas MD Anderson Cancer Center; Pfizer","keywords":"Ipilimumab; Nivolumab; Prostate cancer; Medicine; Oncology; Internal medicine; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001598861,0.0008083577,0.001647378,0.0002123473,0.0002826923,0.001352404,0.0004778741,0.0005899955,0.0026336],"category_scores_gemma":[0.001502214,0.0002752043,0.002259907,0.0003966678,0.0004754336,0.0008363573,0.0002957859,0.001897163,0.0004638459],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000839212,"about_ca_system_score_gemma":0.0009466012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001534347,"about_ca_topic_score_gemma":0.005534545,"domain_scores_codex":[0.9994185,0.0003086483,0.00002338208,0.00009482392,0.00005009724,0.0001046031],"domain_scores_gemma":[0.9993333,0.0002055716,0.0001187315,0.00007462023,0.00003592487,0.0002317314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8321968,0.003649441,0.01850886,0.0008524123,0.006135014,0.0001386856,0.0001813052,0.003830619,0.008152981,0.0004998042,0.004503007,0.1213511],"study_design_scores_gemma":[0.6223844,0.1824756,0.1588603,0.0003308794,0.01266666,0.0005907649,0.0003138516,0.005953821,0.002789692,0.002484305,0.01100637,0.0001434353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909166,0.00434775,0.0002851977,0.0004698811,0.0001145445,0.0002416776,0.001152087,0.00004974787,0.002422593],"genre_scores_gemma":[0.9941332,0.001533065,0.0004554838,0.0005420956,0.0001292369,0.0001698178,0.001875401,0.00002232357,0.001139328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0026336,"threshold_uncertainty_score":0.008810282,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03752139322097603,"score_gpt":0.3103108764788775,"score_spread":0.2727894832579015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}